10月23日，康希诺生物盘中下跌6.15%，报27.0港元，成交额986.8万港元。
消息面上，公司将于10月27日召开董事会审议第三季度业绩，市场进入季报窗口；同时生物科技板块整体偏弱，对股价形成压制。
公司此前中期营收5.47亿元，同比增长46.1%，经调整净亏损收窄至72.10万元；10月中旬又披露收到286.63万元政府补助，预计对利润产生积极影响。但当日同行中云顶新耀跌8.89%，信达生物跌0.92%，康方生物跌0.95%，板块波动放大了个股调整。
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.